Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study
- DOI
- 10.1007/s10147-022-02232-7
- Published
- 2022-08-29
- Container
- International Journal of Clinical Oncology
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1007/s10147-022-02232-7,
title = {Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study},
author = {Shunichi Sugawara and Masashi Kondo and Toshihide Yokoyama and Toru Kumagai and Makoto Nishio and Koichi Goto and Kazuhiko Nakagawa and Takashi Seto and Nobuyuki Yamamoto and Kentarou Kudou and Takayuki Asato and Pingkuan Zhang and Yuichiro Ohe},
year = {2022},
journal = {International Journal of Clinical Oncology},
doi = {10.1007/s10147-022-02232-7},
url = {https://doi.org/10.1007/s10147-022-02232-7}
}RIS
TY - JOUR TI - Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study AU - Shunichi Sugawara AU - Masashi Kondo AU - Toshihide Yokoyama AU - Toru Kumagai AU - Makoto Nishio AU - Koichi Goto AU - Kazuhiko Nakagawa AU - Takashi Seto AU - Nobuyuki Yamamoto AU - Kentarou Kudou AU - Takayuki Asato AU - Pingkuan Zhang AU - Yuichiro Ohe PY - 2022 JO - International Journal of Clinical Oncology DO - 10.1007/s10147-022-02232-7 UR - https://doi.org/10.1007/s10147-022-02232-7 ER -
APA
Sugawara, S., Kondo, M., Yokoyama, T., Kumagai, T., Nishio, M., Goto, K., Nakagawa, K., Seto, T., Yamamoto, N., Kudou, K., Asato, T., Zhang, P., & Ohe, Y. (2022). Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-022-02232-7
Source records
- crossref · retrieved 2026-09-26T20:20:46.698Z